ACP-103 + risperidone

ACP-103 + risperidone is a **combination therapy** composed of ACP-103 (also known as pimavanserin) and risperidone. ACP-103 is a small molecule discovered and developed by Acadia Pharmaceuticals and acts as a potent and selective **inverse agonist of the serotonin 5-HT2A receptor**. Risperidone is a widely used atypical antipsychotic with dopamine D2 receptor and serotonin 5-HT2A receptor antagonist properties. This combination has been investigated primarily for use in **schizophrenia** to enhance antipsychotic efficacy and reduce side effects (such as hyperprolactinemia and motor disturbances) that are associated with D2 antagonism from antipsychotic drugs like risperidone. Preclinical and clinical studies suggest that combining ACP-103 with risperidone may improve efficacy and side effect profiles compared to risperidone alone[1][2][3][4][5][6].

Other names

pimavanserin + risperidone